The EMA recommends two new drugs for people infected with corona. First details at a glance.
+++ 4.00 p.m.: The EU medicines authority EMA has cleared the way for the approval of two further corona drugs * for the treatment of Covid-19. The EMA announced on Thursday in Amsterdam that patients could be treated well with Xevudy and Kineret.
The EU Commission has yet to approve the approval. But that is a matter of form. With these two preparations, a total of five drugs for the treatment of Covid 19 patients will then be approved in the EU.
EMA recommends two corona drugs
Xevudy (sotrovimab) made by GlaxoSmithKline and Vir Biotechnology is a monoclonal antibody. According to the experts, it can prevent worsening of the condition in patients aged 12 and over. Laboratory studies indicated that Xevudy is also effective against the Omikron variant. The EMA experts had previously spoken out positively about the drug, so that it is already being prescribed in some EU member states.
The preparation Kineret can be given to patients with pneumonia who need oxygen. It is already approved in the EU as a remedy for other inflammations. According to the EMA, the product from the Swedish manufacturer Orphan Biovitrum AB can also reduce inflammation in Covid 19 patients and prevent severe damage to the airways.
The European Commissioner for Health, Stella Kyriakides, welcomed the EMA’s recommendation. This means that a wider range of drugs is now available. More would follow in the next few months.
First report from Thursday, December 16, 2021, 3:20 p.m .: Amsterdam – The European Medicines Agency EMA has recommended two new corona drugs. These are the remedies Kineret and Xevudy.
At the end of November, the EMA announced that testing of the two drugs would begin. The agent Xevudy is a so-called monoclonal antibody that adults and adolescents could be treated with in order to prevent serious illness after a corona infection. (do with AFP / dpa) * fr.de is an offer from IPPEN.MEDIA.
